NCT05161806View on ClinicalTrials.gov

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 11, 2022

Primary Completion Date

May 4, 2022

Study Completion Date

May 4, 2022

Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
DRUG

SOK583A1 (40 mg/mL)

SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration

DEVICE

Prefilled Syringe (PFS)

Prefilled Syringe (PFS)

Trial Locations (3)

13088

Sandoz Investigational Site, Liverpool

30060

Sandoz Investigational Site, Marietta

60452

Sandoz Investigational Site, Oak Forest

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY